RARE (Ultragenyx Pharmaceutical Inc.) Gross Profit Rate

RARE (Ultragenyx Pharmaceutical Inc.) - company brandmark

This chart of gross profit as a percentage of revenue reflects the strategic acquisitions and commercialization of orphan drugs by Ultragenyx Pharmaceutical (RARE) management. The foundation relies on patent protection and lobbying, despite stringent FDA oversight. However, a narrow patient market and R&D expenses create financial pressure. Today, 78.20 expresses the current value of the metric, helping to define the long-term investment horizon.

ultragenyx.com (RARE) Gross Profitability: for the period 07/04/2022 - 11/20/2026

Financial and market metric breakdowns for Ultragenyx Corp (RARE)

- current price and projected stock value:
- business market valuation indicators:
- cash and cash flow statistics:
Fundamental valuation:RARE, Ultragenyx
Core merchandise of Ultragenyx Pharma

To identify the sector's fundamental leaders, the analyst evaluates the business's ability to generate excess cash flow after covering direct production costs. This metric measures the share of sales profit which, in the case of Ultragenyx Pharmaceutical (RARE), is supported by the stability of humanitarian developments independent of geopolitical risks, as clearly evidenced by the gross profit margin.

Direct competitors

Return on Gross Profit Tempus AI Inc|QGEN (Qiagen NV) - Gross Margin|Return on Gross Profit Ionis Pharma (IONS)|Gross Profitability Repligen Corp (RGEN)|RNA - Gross Profit Margin|crisprtx.com - Return on Gross Profit|Gross Profit Rate WGS|Beam Tx - Gross Margin|SRPT - Gross Margin|TWST (Twist Bio) - Return on Gross Profit|Gross Return on Sales TXG|Return on Gross Profit NTLA|Stoke Therapeutics Inc (STOK) - Return on Sales by Gross Profit|Gross Margin BLFS|Gross Profitability WVE (Wave Life Sciences Corp)|Gross Profitability Maze Therapeutics MAZE|Gross Profit Rate SION|PRME - Gross Profitability|Return on Sales by Gross Profit Taysha TSHA|QURE: Gross Margin|Return on Gross Profit MeiraGTx PLC|RGNX (REGENXBIO Inc) - Gross Margin|solidbio.com (SLDB) - Return on Sales by Gross Profit|Gross Profitability Ocugen Corp (OCGN)|Pacific Biosciences of California, Inc. - Gross Return on Sales|Benitec Biopharma - Return on Gross Profit|DSGN: Gross Return on Sales|RCKT: Return on Gross Profit|FDMT - Gross Margin|LXEO: Gross Margin|Korro Bio Inc. - Gross Profit Rate|EDIT (editasmedicine.com) - Gross Margin|Gross Profitability SLN|Gross Profitability ProQR Therapeutics NV (PRQR)|Codexis - Gross Return on Sales|Gross Profitability Sangamo SGMO|NAUT: Gross Return on Sales|MGX: Return on Gross Profit|Gross Profit Margin Precision BioSciences|GBIO (generationbio.com) - Return on Gross Profit|Gross Profit Margin boundlessbio.com (BOLD)|XCUR (exicuretx.com) - Gross Margin|Gross Return on Sales IMNN (Imunon, Inc.)|Gross Margin PHIO|MBIO - Gross Profit Margin|Gross Margin RNAZ (TransCode Therapeutics)|bionanogenomics.com (BNGO) - Gross Profit Margin|Applied DNA - Gross Margin|Gross Profit Margin Bluebird Bio|ImmunoPrecise (IPA) - Gross Profitability|Gross Profitability Margin OMGA (Omega)|Gross Profitability Singular Genomics Systems|Gross Profit Margin regulusrx.com RGLS|Gross Profitability Syros Pharmaceuticals Inc. (SYRS)|Return on Sales by Gross Profit Codex DNA|Gross Profitability TRACON TCON|Unity Biotechnology, Inc - Gross Profitability